

0001171843-25-0001056-K GALAPAGOS NV 2025010820250108060008060009060009 0 0001171843-25-000105 6-K 2
20250107 20250108 20250108 GALAPAGOS NV 0001421876 2834 000000000 6-K 34 001-37384 25516416 GEN DE
WITTELAAN L11 A3 2800 MECHELEN C9 00000 3215342900 GEN DE WITTELAAN L11 A3 2800 MECHELEN C9
00000 6-K 1 f6k_010825.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-
37384 GALAPAGOS NV (Translation of registrant's name into English) Generaal De Wittelaan L11 A3 2800 Mechelen,
Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [] The information contained
in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration
Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-
231765, 333-249416, 333-260500, 333-268756, 333-275886, and 333-283361). On January 7, 2025, the Registrant
issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c)
Exhibit 99.1. Press release dated January 7, 2025 SIGNATURES Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized. GALAPAGOS NV (Registrant) Date: January 8, 2025 /s/ Annelies
Denecker Annelies Denecker Company Secretary EX-99.1 2 exh_991.htm PRESS RELEASE
Edgar Filing EXHIBIT 99.1 Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference Mechelen,
Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company
will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in
San Francisco. A live webcast of the presentation will be accessible on the Investors page of the Company's website
at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be
archived for up to 30 days. In addition, Galapagos management will host a sell-side analyst breakfast in San Francisco
on Tuesday, January 14, 2025 at 8:00 am PT. Analysts interested in attending should reach out the Galapagos Investor
Relations team at ir@glpg.com. About Galapagos We are a biotechnology company with operations in Europe and the
U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and
quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative
approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology.
With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, and the financial
strength to invest strategically for the near- and long-term, we are committed to challenging the status quo and
delivering results for our patients, employees, and shareholders. Our goal is not just to meet current medical needs but
to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most. For
additional information, please visit www.glpg.com or follow us on LinkedIn or X. For further information, please
contact: Media inquiries: Marieke Vermeersch +32 479 490 603 Jennifer Wilson + 44 7539 359 676 media@glpg.com
Investor inquiries: Srikant Ramaswami +1 412 699 0359 Sandra Cauwenberghs +32 495 58 46 63 ir@glpg.com
Forward-looking statements This press release may contain forward-looking statements. Such forward-looking
statements are not guarantees of future results. These forward-looking statements speak only as of the date of
publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in
this document, unless specifically required by law or regulation.